Aromatase inhibitors: Pharmacological aspects;Les inhibiteurs de l'aromatase: Aspects pharmacologiques

Bulletin du Cancer

Volumn 87, Issue SPEC. ISS., 2000, Pages 23-29

  De Cremoux P ^a  

^a INSTITUT CURIE   (France)

Author keywords

Aromatase inhibitor; Breast cancer; Estrogen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; STEROID; VOROZOLE;

AROMATIZATION; ASTHENIA; ATAXIA; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME ACTIVITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONE DEPENDENCE; HUMAN; MUSCLE CRAMP; POSTMENOPAUSE; RASH; REVIEW; SOMNOLENCE;

AMINOGLUTETHIMIDE; ANDROSTADIENES; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ENZYME INHIBITORS; FADROZOLE; FEMALE; HUMANS; NITRILES; TRIAZOLES;

EID: 0034468225     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. The importance of local synthesis of estrogen within the breast
2. Endogenous concentrations and subcellular distribution of estrogens in normal and malignant human breast tissue
3. Regulation of estrogen concentrations in human breast tissues
4. 2DH) activity in T47D cells
5. Studies on the mechanism of oestrogen biosynthesis VII. The development of inhibitors of the enzyme system in human placenta
6. Aromatase inhibitors and breast cancer
7. Preliminary trial of aminoglutethimide in breast cancer
8. Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer
9. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors
10. Inactivation of aromatase activity in vitro by 4 hydroxy androstene-3, 17-dione and 4-acetory androstene 3, 17-dione and sustained effectes in vivo
11. Formestane: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer
12. Anastrozole: A new generation in aromatase inhibition clinical pharmacology
13. 4-Hydroxyandrostene dione: A new treatment for postmenopausal patients with breast cancer
14. Concentrations of estrone and 4-hydroxyandrostenedione in malignant and normal breast tissues
15. Treatment of advanced post menopausal breast cancer with an aromatase inhibitor 4-hydroxandrostenedione phase II reporr
16. 6-methyleneandrosra 1,4-diene-3,17-dione (FCE 24304): A new irreversible aromatase inhibitor
17. Novel irreversible aromatase inhibitors
18. Novel aromatase and 5-reductase inhibitors
19. Phase I and endocrine study of exemestane (FCE 24304): A new aromatase inhibitor, in post menopausal women
20. In vivo inhibition of aromatization by exemestane: A novel irreversible aromatase inhibitor in post menopausal breast cancer patients
21. Effect of good and formulation on the pharmacokinetics PKI and pharmacodynamics (PD) of a single oral dose of exemestane (Aromasin™ EXE) abs. N° 741
22. Endocrine and clinical effect of exemestane (PNU 155971): A novel steroidal aromatase inhibitor in post menopausal breast cancer patients a phase I study
23. Exemestane
24. Aminoglutethimide as an inhibitor of adrenal steroidogenesis mechanisms of action and therapeutic trials
25. Clinical applications of new aromatase inhibitors
26. Endocrine effect of low dose aminoglutethimide alone in advanced postmenopausal breast cancer
27. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer
28. Anastrozole: A review of its use in the management of postmenopausal women with advanced breast cancer
29. Arimidex (2D1033): A selective potent inhibitor of aromatase in post menopausal female volunters
30. A randomised trial comparing two doses of the new selective arome inhibitor anastrozole (Arimidex) with megestrol acetate in post menopausal patients with advanced breast cancer patients
31. A phase III trial comparing anastrozole (1 and 10 mg) a parent and selective aromatase inhibitor with megesrrol acetate in post menopausal women with advanced breast carcinoma
32. Letrozole A review of its use in the management of postmenopausal women with advanced breast cancer
33. Aromatase inhibitors and breast cancer
34. In vivo measurement of aromatase inhibition by letrozole (CGS 20367) in post menopausal patients with breast cancer
35. Use of ultrasensitive recombinanr all bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor letrozole
36. R76713 and enanthiomer selective nonsteroidal inhibitors of the cytochrome P450-dependent estrogen synthesis
37. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibition vivo in health postmenopausal women
38. Phase II study of vorozole (R83842): A new aromatase inhibitor in post menopausal women with advanced breast cancer
39. Vorozole a specific non steroidal aromatase inhibitor
40. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors
41. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with non steroidal aromatase inhibitor CGS 16949A
42. Aromatase inhibitors: Mechanisms for non-steroidal inhibitors
43. The new aromatase inhibitor CGS16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro